Work

CD8+ T cell stimulation with pegylated recombinant human IL-10 in the patient with advanced solid tumors - a Phase I study

Year: 2015

Type: conference-abstract

Abstract: Meeting abstracts In preclinical studies, PEGylated IL-10 (PEG-IL-10) but not non-PEG IL-10 induces tumor rejection by the directly activating and increasing the proliferation of tumor specific CD8 T cells within the tumor. PEG-IL-10 activates STAT3 and STAT1 in tumor infiltrating CD8 T cells. PEG-

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-3-s2-p204

Authors: Aung Naing, Jeffrey R Infante, Kyriakos P Papadopoulos, Karen A Autio, Deborah J Wong, Gerald S Falchook, Manish R Patel, Shubham Pant, Melinda Whiteside, Johanna Bendell, Todd M Bauer, Filip Janku, Milind Javle, Rivka Colen, Nizar Tannir, Martin Oft

Institutions: The University of Texas MD Anderson Cancer Center, Sarah Cannon, Tennessee Oncology, South Texas Accelerated Research Therapeutics, Memorial Sloan Kettering Cancer Center, University of California, Los Angeles, Sarah Cannon Research Institute, HealthONE, Florida Cancer Specialists & Research Institute, University of Oklahoma

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490

OpenAlex ID: W2147406792

Cites:

Cited by: 3

Related to: 10